Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2

被引:34
|
作者
Chuang, Yu-Hsuan [1 ]
Lill, Christina M. [6 ]
Lee, Pei-Chen [9 ]
Hansen, Johnni [10 ]
Lassen, Christina F. [10 ]
Bertram, Lars [7 ,8 ,11 ]
Greene, Naomi [1 ]
Sinsheimer, Janet S. [2 ,4 ]
Ritz, Beate [1 ,3 ,5 ]
机构
[1] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, 650 Charles E Young Dr, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Environm Hlth Sci, Los Angeles, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet & Biomathemat, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
[6] Univ Lubeck, Inst Neurogenet, Genet & Mol Epidemiol Grp, Lubeck, Germany
[7] Univ Lubeck, Inst Neurogenet, Interdisciplinary Platform Genome Analyt LIGA, Lubeck, Germany
[8] Univ Lubeck, Inst Integrat & Expt Genom, Interdisciplinary Platform Genome Analyt LIGA, Lubeck, Germany
[9] Natl Taipei Univ Nursing Hlth Sci, Coll Healthcare Adm & Management, Dept Hlth Care Management, Taipei, Taiwan
[10] Danish Canc Soc, Res Ctr, Copenhagen, Denmark
[11] Imperial Coll Sci Technol & Med, Fac Med, Sch Publ Hlth, London, England
基金
美国国家卫生研究院;
关键词
Parkinson's disease; Caffeine; Adenosine A2A receptor (ADORA2A); Cytochrome P450 1A2 (CYP1A2); Meta-analysis; RECEPTOR INTERACTIONS; ADENOSINE RECEPTOR; CAFFEINE; RISK; ASSOCIATION; SMOKING; NEUROPROTECTION; POLYMORPHISMS; CONNECTION; MODEL;
D O I
10.1159/000450855
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background and Purpose: Drinking caffeinated coffee has been reported to provide protection against Parkinson's disease (PD). Caffeine is an adenosine A2A receptor (encoded by the gene ADORA2A) antagonist that increases dopaminergic neurotransmission and Cytochrome P450 1A2 (gene: CYP1A2) metabolizes caffeine; thus, gene polymorphisms in ADORA2A and CYP1A2 may influence the effect coffee consumption has on PD risk. Methods: In a population-based case-control study (PASIDA) in Denmark (1,556 PD patients and 1,606 birth year-and gender-matched controls), we assessed interactions between lifetime coffee consumption and 3 polymorphisms in ADORA2A and CYP1A2 for all subjects, and incident and prevalent PD cases separately using logistic regression models. We also conducted a meta-analysis combining our results with those from previous studies. Results: We estimated statistically significant interactions for ADORA2A rs5760423 and heavy vs. light coffee consumption in incident (OR interaction = 0.66 [95% CI 0.46-0.94], p = 0.02) but not prevalent PD. We did not observe interactions for CYP1A2 rs762551 and rs2472304 in incident or prevalent PD. In meta-analyses, PD associations with daily coffee consumption were strongest among carriers of variant alleles in both ADORA2A and CYP1A2. Conclusion: We corroborated results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our results also suggest that survivor bias may affect results of studies that enroll prevalent PD cases. (C) 2017 S. Karger AG, Basel
引用
收藏
页码:192 / 200
页数:9
相关论文
共 50 条
  • [31] Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson Disease
    Hamza, Taye H.
    Hill-Burns, Erin M.
    Scott, William K.
    Vance, Jeffrey M.
    Factor, Stewart A.
    Zabetian, Cyrus P.
    Payami, Haydeh
    PLOS GENETICS, 2014, 10 (11):
  • [32] CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension
    Palatini, Paolo
    Ceolotto, Giulio
    Ragazzo, Fabio
    Dorigatti, Francesca
    Saladini, Francesca
    Papparella, Italia
    Mos, Lucio
    Zanata, Giuseppe
    Santonastaso, Massimo
    JOURNAL OF HYPERTENSION, 2009, 27 (08) : 1594 - 1601
  • [33] CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction
    Mahdavi, Sara
    Palatini, Paolo
    El-Sohemy, Ahmed
    JAMA NETWORK OPEN, 2023, 6 (01) : E2247868
  • [34] Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
    Djordjevic, Natasa
    Ghotbi, Roza
    Bertilsson, Leif
    Jankovic, Slobodan
    Aklillu, Eleni
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (04) : 381 - 385
  • [35] Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
    Natasa Djordjevic
    Roza Ghotbi
    Leif Bertilsson
    Slobodan Jankovic
    Eleni Aklillu
    European Journal of Clinical Pharmacology, 2008, 64 : 381 - 385
  • [36] Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene:: lack of a polymorphism in CYP1A2 in Caucasians
    Welfare, MR
    Aitkin, M
    Bassendine, MF
    Daly, AK
    PHARMACOGENETICS, 1999, 9 (03): : 367 - 375
  • [37] Mechanisms of Gene-Environment Interactions in Parkinson’s Disease
    Fleming S.M.
    Current Environmental Health Reports, 2017, 4 (2) : 192 - 199
  • [38] Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism
    Natasa Djordjevic
    Roza Ghotbi
    Slobodan Jankovic
    Eleni Aklillu
    European Journal of Clinical Pharmacology, 2010, 66 : 697 - 703
  • [39] ADORA2A Gene Variation, Caffeine, and Emotional Processing: A Multi-level Interaction on Startle Reflex
    Katharina Domschke
    Agnieszka Gajewska
    Bernward Winter
    Martin J Herrmann
    Bodo Warrings
    Andreas Mühlberger
    Katherina Wosnitza
    Evelyn Glotzbach
    Annette Conzelmann
    Andrea Dlugos
    Manfred Fobker
    Christian Jacob
    Volker Arolt
    Andreas Reif
    Paul Pauli
    Peter Zwanzger
    Jürgen Deckert
    Neuropsychopharmacology, 2012, 37 : 759 - 769
  • [40] ADORA2A Gene Variation, Caffeine, and Emotional Processing: A Multi-level Interaction on Startle Reflex
    Domschke, Katharina
    Gajewska, Agnieszka
    Winter, Bernward
    Herrmann, Martin J.
    Warrings, Bodo
    Muehlberger, Andreas
    Wosnitza, Katherina
    Glotzbach, Evelyn
    Conzelmann, Annette
    Dlugos, Andrea
    Fobker, Manfred
    Jacob, Christian
    Arolt, Volker
    Reif, Andreas
    Pauli, Paul
    Zwanzger, Peter
    Deckert, Juergen
    NEUROPSYCHOPHARMACOLOGY, 2012, 37 (03) : 759 - 769